MR. JASON C CHANDLER M.D NPI 1295778330

NPI Details

MR. Jason C Chandler, M.D is a medical oncology internal medicine in Germantown, TN with 23 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. MR. Jason C Chandler, M.D NPI is 1295778330. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TENNESSEE, HSC, COLLEGE OF MEDICINE
Graduation Year:2003

The provider's business location address is:

7945 WOLF RIVER BOULEVARD
GERMANTOWN, TN
ZIP 38138
Phone: (901) 683-0055
Fax: (901) 922-6701

The NPI 1295778330 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, durvalumab, 10 mg (HCPCS:J9173)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Liver function blood test panel (HCPCS:80076)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Nephelometry, test method using light (HCPCS:83883)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Uric acid level, blood (HCPCS:84550)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Therapy procedure using manual technique, each 15 minutes (HCPCS:97140)
• Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99490)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Unclassified drugs (HCPCS:J3490)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Red blood count, automated test (HCPCS:85045)
• Folic acid level, serum (HCPCS:82746)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Blood creatinine level (HCPCS:82565)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Magnesium level (HCPCS:83735)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Blood test, clotting time (HCPCS:85610)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Flow cytometry technique for dna or cell analysis, 16 or more markers (HCPCS:88189)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes (HCPCS:97110)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Therapy procedure using functional activities (HCPCS:97530)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Rheumatoid factor level (HCPCS:86431)
• Training for self-care or home management, each 15 minutes (HCPCS:97535)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Blood glucose (sugar) level (HCPCS:82947)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Phosphate level (HCPCS:84100)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) (HCPCS:G0506)
• Injection, mannitol, 25% in 50 ml (HCPCS:J2150)
• Vitamin d-3 level (HCPCS:82306)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment (HCPCS:99453)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Automated urinalysis test (HCPCS:81003)
• Declotting of central venous tube (HCPCS:36593)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)

The enumeration date for this NPI number is 6/14/2006 and was last updated on 7/10/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.